DAB2IP and prostate cancer: In this study we show that pretreatment tumor DAB2IP status and not EZH2 correlates with worse rates of biochemical failure, castration resistance, and distant metastasis after the standard of care treatment for these high‐risk prostate cancer patients including definitive radiation therapy and androgen deprivation.